Alpine Immune Sciences Inc (ALPN)
65.00
+0.04
(+0.06%)
USD |
NASDAQ |
May 17, 16:00
65.00
0.00 (0.00%)
After-Hours: 20:00
Alpine Immune Sciences Cash from Financing (Quarterly): 19.35M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 19.35M |
December 31, 2023 | 156.61M |
September 30, 2023 | 1.201M |
June 30, 2023 | 8.398M |
March 31, 2023 | -1.087M |
December 31, 2022 | 11.54M |
September 30, 2022 | 92.82M |
June 30, 2022 | -1.02M |
March 31, 2022 | -0.65M |
December 31, 2021 | 10.87M |
September 30, 2021 | 89.68M |
June 30, 2021 | 0.009M |
March 31, 2021 | 0.202M |
December 31, 2020 | -0.011M |
September 30, 2020 | 56.39M |
June 30, 2020 | 0.002M |
March 31, 2020 | 5.00M |
December 31, 2019 | 0.00 |
September 30, 2019 | 1.646M |
June 30, 2019 | -0.509M |
March 31, 2019 | 23.12M |
Date | Value |
---|---|
December 31, 2018 | -0.50M |
September 30, 2018 | -0.498M |
June 30, 2018 | 0.00 |
March 31, 2018 | 0.007M |
December 31, 2017 | 0.00 |
September 30, 2017 | 42.69M |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | 0.063M |
September 30, 2016 | 0.011M |
June 30, 2016 | 0.092M |
March 31, 2016 | |
December 31, 2015 | 0.062M |
September 30, 2015 | -2.104M |
June 30, 2015 | 80.88M |
March 31, 2015 | |
December 31, 2014 | 29.89M |
September 30, 2014 | 4.088M |
June 30, 2014 | 2.603M |
March 31, 2014 | 4.582M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.087M
Minimum
Mar 2023
156.61M
Maximum
Dec 2023
22.52M
Average
1.424M
Median
Cash from Financing (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | -357.50M |
Eliem Therapeutics Inc | 0.015M |
Regeneron Pharmaceuticals Inc | 47.10M |
Vera Therapeutics Inc | 276.54M |
Eyenovia Inc | 3.133M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -27.69M |
Cash from Investing (Quarterly) | -2.562M |
Free Cash Flow | -80.96M |
Free Cash Flow Per Share (Quarterly) | -0.4327 |
Free Cash Flow to Equity (Quarterly) | -27.71M |
Free Cash Flow Yield | -2.30% |